<sup>227</sup>Th-Labeled Anti-CD22 Antibody (BAY 1862864) in Relapsed/Refractory CD22-Positive Non-Hodgkin Lymphoma: A First-in-Human, Phase I Study.

导出原文传递

翻译打印收藏纠错

作者： Ola,Lindén ^[1] ; Andrew T,Bates ^[2] ; David,Cunningham ^[3] ; Cecilia,Hindorf ^[4] ; Erik,Larsson ^[4] ; Adriaan,Cleton ^[5] ; Joerg,Pinkert ^[6] ; Funan,Huang ^[7] ; Friedhelm,Bladt ^[8] ; Hartwig,Hennekes ^[8] ; Liv-Ingrid,Oedegaardstuen ^[9] ; Isrid,Sturm ^[8] ; Christopher,McNamara ^[10]

作者单位： Department of Oncology, Lund University Hospital, Lund, Sweden. ^[1] Clinical Oncology Department, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom. ^[2] Gastrointestinal and Lymphoma Unit, The Royal Marsden Hospital, London, United Kingdom. ^[3] Department of Radiation Physics, Skåne University Hospital, Lund, Sweden. ^[4] Translational Sciences Asia, Bayer Healthcare Co. Ltd., Beijing, China. ^[5] Pharmacovigilance, Benefit-Risk Management Oncology, Bayer AG, Berlin, Germany. ^[6] Strategic Business Unit Oncology, Bayer Healthcare US, Whippany, New Jersey, USA. ^[7] Strategic Business Unit Oncology, Bayer AG, Berlin, Germany. ^[8] Research and Development, Bayer AS, Oslo, Norway. ^[9] Department of Haematology, University College London Hospital, London, United Kingdom. ^[10]

关键词 227Th CD22 first-in-human non-Hodgkin lymphoma targeted alpha therapy